Industry News

Teva Pharmaceutical Industries Ltd. in the New York court regarding the acquisition of the Mexican firm Rimsa will probably not be the only legal action Teva will have to conduct regarding this acquisition. Yesterday, the Central District Court received a request to file a derivative suit against Teva, company directors and executives, including CEO Erez Vigodman and CFO Eyal Desheh, and against Citigroup, which provided Teva with consultation..."/>
Shareholders sue Teva over Rimsa acquisition [Globes, Tel Aviv, Israel]
Intrexon Corporation, a leader in synthetic biology, today announced that pursuant to New York Stock Exchange Rule 303 A.08 it granted Geno J. Germano an employment inducement award in connection with Mr. As Intrexon previously disclosed in a Current Report on Form 8- K filed on May 17, 2016, the Intrexon Compensation Committee approved the award to Mr. Germano of options to purchase an aggregate of 2,000,000 shares of the Company's common..."/>
Intrexon Grants Employment Inducement Award Pursuant to NYSE Rule 303A.08
RepliCel Life Sciences Inc., a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to provide an update on the licensing and co-development of its RCH-01 product with Shiseido Company. As announced in July, RepliCel's RCH-01 product, for the treatment of androgenetic alopecia, is now under clinical investigation at Tokyo Medical University Hospital and Toho University..."/>
RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
UnitedHealth Group, are taking immediate action to help people in western Wisconsin who may be affected by the recent flooding. This includes assisting health plan participants who may need to make alternate..."/>
UnitedHealthcare and Optum Support People Affected by Floods in Western Wisconsin
Pieris Pharmaceuticals, Inc., a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform, announced that it has today presented new preclinical data demonstrating in vivo efficacy of its lead 4-1 BB- based bispecific cancer immunotherapeutic drug candidate, PRS-343, at the 2016 CRI-CIMT-AACR International Cancer Immunotherapy Conference- Translating Science into Survival, taking place in New..."/>
Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Infinity Pharmaceuticals, Inc. today announced initial clinical and new preclinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. Preliminary Phase 1 results from nine patients with advanced solid tumors show that the safety, pharmacokinetics and pharmacodynamics of IPI-549 monotherapy treatment appear favorable. Additionally, new preclinical data..."/>
Infinity Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Cigna will give it more market power, saving the insurer billions of dollars and reducing charges for customers. Department of Justice, which is seeking to stop the nation's second-largest health insurer from buying Bloomfield-based Cigna, argues that more leverage at a larger Anthem could hurt doctors and hospitals, and therefore hurt the quality of health care..."/>
Anthem Says Cigna Merger Will Cut Costs, Create Savings [The Hartford Courant]
CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the closing of its previously announced underwritten public offering of 2,250,000 shares of its common stock at a public offering price of $4.00 per share, before deducting underwriting discounts and commissions and estimated..."/>
CareDx Announces Closing of Public Offering of Common Stock
Amgen today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life-sciences and biotech startup companies in Massachusetts. LabCentral is an innovative, shared laboratory space designed as a launch pad for premier high-impact life-sciences and biotech startups. As one of LabCentral's platinum sponsors, Amgen can nominate up to two..."/>
Amgen Opens Nomination Process For LabCentral Residency
Navidea Biopharmaceuticals, Inc. today announced that its Board of Directors has appointed Michael M. Goldberg, M.D. as President and Chief Executive Officer effective September 22, 2016. The Board of Directors has also appointed Eric K. Rowinsky M.D., a Navidea board member since 2010, as Chairman of Navidea’ s Board, a position previously held by Dr."/>
Navidea Appoints Michael M. Goldberg, M.D. President and Chief Executive Officer
MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced an underwritten public offering of 3,800,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30- day option to purchase up to an additional..."/>
MyoKardia Announces Proposed Public Offering of Common Stock
Biodel Inc. today announced that its 2016 annual meeting of stockholders has been set for October 24, 2016. At that meeting, stockholders will vote on, among other things, matters necessary to complete Biodel's planned transaction with Albireo Limited pursuant to a previously announced share exchange agreement, including the issuance of shares of Biodel's common stock in the transaction and a proposed reverse stock split of Biodel's common stock at a..."/>
Biodel Announces 2016 Annual Meeting of Stockholders Set for October 24, 2016; Outlines Plan to Regain Compliance With Nasdaq Listing Requirements
Pfizer Inc.' s pending acquisition of small molecule biopharmaceutical company Medivation, Inc., the company said. Pfizer now expects to complete the acquisition in 3 Q16. The closing of the tender offer remains subject to other customary closing conditions, including the tender of a majority of the outstanding..."/>
Pfizer Clears US Antitrust Hurdle in Acquisition of Medivation
Parexel International Corp. has entered into a definitive agreement to acquire US-based biopharmaceutical industry service provider ExecuPharm, Inc. the company said on Monday. The acquisition is expected to close in the next three weeks. Terms of the transaction were not disclosed."/>
Parexel to Acquire Biopharmaceutical Outsourced Services Provider ExecuPharm
Cerecor Inc. has acquired exclusive, worldwide rights from US drugmaker Eli Lilly and Company to develop and commercialise LY3130418, the company said on Monday. CERC-611 is a potent and selective Transmembrane AMPA Receptor Regulatory Proteins y8-dependent AMPA receptor antagonist. TARPs are a fairly recently discovered family of proteins that have been found to associate with and modulate the activity of AMPA..."/>
Cerecor Acquires Rights to Epilepsy Drug from Lilly
NuVasive, Inc., a leading medical device company focused on transforming spine surgery, today announced that the Company will release its third quarter 2016 earnings results before the markets open on Wednesday, October 26, 2016.. NuVasive will hold a conference call on Wednesday, October 26, 2016 at 8:30 a.m. ET/ 5:30 a.m. PT to discuss the results of its financial performance for the third quarter 2016. The dial-in numbers are 1-877-407-9039 for..."/>
NuVasive Announces Conference Call and Webcast of Third Quarter 2016 Results
Rosetta Genomics Ltd., a leading developer and provider of microRNA-based and other molecular diagnostics, reports financial results for the three and six months ended June 30, 2016.."/>
Rosetta Genomics Reports 2016 Second Quarter Financial Results
Prothena Corporation plc, a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that its President and Chief Executive Officer Dale Schenk, PhD, who announced in December 2014 that he had been diagnosed with and was undergoing treatment for pancreatic cancer, is taking a medical leave of absence in order to focus full time on his health."/>
Prothena Announces President and CEO Dr. Dale B. Schenk to Take Medical Leave
Jazz Pharmaceuticals plc today announced that patient enrollment has been completed for its two Phase 3 studies evaluating JZP-110 in excessive sleepiness associated with obstructive sleep apnea. "We are pleased to have reached this important milestone in our Phase 3 program," said Karen Smith, M.D., Ph.D., global head of research and development and chief medical officer of Jazz Pharmaceuticals. "We look forward to reporting the top-line results..."/>
Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea
Amgen and UCB today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. Romosozumab works by binding and inhibiting the activity of the protein sclerostin, a protein naturally occurring in the bone, thereby..."/>
Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab
Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, today announced three poster presentations have been accepted by the Society for Immunotherapy of Cancer’ s 31st Annual Meeting& Associated Programs taking place from Nov. 9-13 at Gaylord National Hotel& Convention Center in National Harbor, Md. The poster presentations showcase the potential of Advaxis’ Lm Technology™ immunotherapies for monotherapy and..."/>
Advaxis’ Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology635 Articles
Consumer Discretionary591 Articles
Financials392 Articles
Industrials372 Articles
Health Care356 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at